Annual General Meeting

Oxford Biomedica PLC
09 May 2008


FOR IMMEDIATE RELEASE                                                 9 MAY 2008


                                OXFORD BIOMEDICA

                             ANNUAL GENERAL MEETING


Oxford, UK - 9 May 2008: Oxford BioMedica (LSE: OXB), a leading gene therapy
company, announced today that all resolutions were duly passed at its Annual
General Meeting, held today in London.


In accordance with Listing Rule 9.6.18, the following resolutions are those
which were passed at the meeting concerning special business (as defined by the
Company):


   •Resolution 9: to empower the Directors to allot equity securities,
    pursuant to section 80 of the Companies Act 1985 (the 'Act'), up to an
    aggregate nominal amount of £1,129,256;


   •Resolution 10: to empower the Directors to allot equity securities for
    cash, pursuant to section 95 of the Act as if section 89(1) of the Act did
    not apply to such allotment, up to an aggregate nominal amount representing
    5 per cent of presently issued shares; and


   •Resolution 11: in addition to the authority contained in Resolution 10,
    to empower the Directors to allot equity securities for cash, pursuant to
    section 95 of the Act as if section 89(1) of the Act did not apply to any
    such allotment up to an aggregate amount representing 5 per cent of
    presently issued shares.


Certified copies of the document setting out the above resolutions passed at the
2008 AGM have been submitted to the UK Listing Authority and will shortly be
made available for inspection at the UK Listing Authority's Document Viewing
Facility, which is situated at The Financial Services Authority, 25 The North
Colonnade, Canary Wharf, London, E14 5HS.


The results of the proxy voting in advance of the meeting and Notice of 2008 AGM
(giving the full text of each of the above resolutions) can be viewed by
visiting our website at www.oxfordbiomedica.co.uk.


                                     -Ends-


For further information, please contact:

Oxford BioMedica plc:
Professor Alan Kingsman, Chief Executive     Tel: [phone]

JPMorgan Cazenove Limited:
James Mitford/ Gina Gibson                   Tel: [phone]

City/Financial Enquiries:
Lisa Baderoon/ Mark Court/ Mary-Jane Johnson Tel: [phone]
Buchanan Communications

Scientific/Trade Press Enquiries:
Holly Griffiths/ Katja Stout/ Claire Mosley  Tel: [phone]
College Hill Life Sciences

US Enquiries:
Thomas Fechtner                              Tel: [phone]
The Trout Group LLC


Notes to editors

Oxford BioMedica

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in
cancer immunotherapy and gene-based therapies. The Company was established in
1995, as a spin-out from Oxford University, and is listed on the London Stock
Exchange.

The Company has a platform of gene delivery technologies, which are based on
highly engineered viral systems. Oxford BioMedica also has in-house clinical,
regulatory and manufacturing know-how. The lead product candidate is TroVax(R),
a therapeutic vaccine for multiple solid cancers, which is licensed to
sanofi-aventis for global development and commercialisation. TroVax is in Phase
III development. Oxford BioMedica has three other products in clinical
development, including ProSavin(R), a novel gene-based treatment for Parkinson's
disease, in a Phase I/II trial. The Company is underpinned by over 80 patent
families, which represent one of the broadest patent estates in the field. The
Company has a staff of approximately 85. Oxford BioMedica has collaborations
with sanofi-aventis, Wyeth, Sigma-Aldrich, MolMed and Virxsys. Technology
licensees include Biogen Idec, Merck & Co, GlaxoSmithKline and Pfizer.

Further information is available at www.oxfordbiomedica.co.uk



                      This information is provided by RNS
            The company news service from the London Stock Exchange